This Phase II Trial is Studying Sunitinib to See How Well it Works When Given as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer Which is Previously Treated With Combination Chemotherapy.
- To investigate the effect of sunitinib malate on the progression-free survival of
patients with stage IIIB or IV non-small cell lung cancer Secondary
- To evaluate the toxicity of sunitinib when administered in the maintenance setting.
- To evaluate the additional response rate to sunitinib malate when administered in the
- To evaluate the overall survival of patients treated with sunitinib. After completion
of study treatment, patients are followed every 2 months for 1 year, every 6 months for
1 year, and periodically for 3 years.
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
yang zhenzhou, doctor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
United States: Food and Drug Administration